MEDIUM confidence
Researched 2026-07-22 22:42 · profile: researcher
Programme Thesis
This programme funds collaborative research projects that advance drug development and regulatory science, aiming to improve the safety, efficacy, and regulatory evaluation of new therapies. It exists to foster partnerships between academic, industry, and regulatory stakeholders to address critical gaps in the drug development pipeline.
Selection Criteria
- Scientific and technical merit of the proposed research
- Relevance to FDA regulatory science priorities (e.g., novel methodologies, safety assessment, clinical trial innovation)
- Qualifications and experience of the principal investigator and team
- Strength of collaborative partnerships (across sectors or disciplines)
- Potential impact on public health and regulatory decision-making
- Feasibility of the project plan and budget
Past Winners / Cohort Profiles
Past winners typically include academic researchers with strong ties to FDA or industry partners, often with prior experience in drug development or regulatory science. Examples include teams developing novel biomarkers, computational models for toxicity prediction, or innovative clinical trial designs. Named examples are not available on the page.
Ideal Candidate Fingerprint
The ideal applicant is an established investigator (often PhD or MD) with a track record in drug development or regulatory science, leading a multi-institutional team that includes FDA collaborators. They propose a well-defined, high-impact project that directly addresses a regulatory science gap, with clear milestones and dissemination plans.
Recommended Framing
Eniola should frame the CCT model as a novel computational framework for predicting addiction liability of new chemical entities, directly relevant to FDA's regulatory need for better preclinical safety and abuse-potential assessment. Highlight the provisional patent, endorsements from Berridge and Gershman, and the Bayesian validation as evidence of rigor and translational potential. Emphasize the collaborative angle by proposing partnerships with US-based addiction researchers or regulatory scientists to strengthen the application.
Watch Out
Eniola is an independent researcher without a PhD or formal academic appointment, which may be a disadvantage for a grant typically awarded to established investigators. The programme likely requires a US-based institution as the lead applicant; Eniola's Nigerian affiliation may need a US collaborator to serve as PI. Also, the deadline and amount are not specified, so timing and budget alignment are uncertain.